A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma
Phase of Trial: Phase II
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Glembatumumab vedotin (Primary)
- Indications Uveal melanoma
- Focus Therapeutic Use
- 01 Jun 2017 Planned primary completion date changed from 31 Oct 2017 to 28 Oct 2017.
- 01 Jun 2017 Status changed from recruiting to suspended.
- 24 May 2017 Planned number of patients changed from 34 to 35.